Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Danny Luan, MPH, Paul J Christos, Dr.P.H., M.S., Michael Ancharski, MLS(ASCP), Danielle Guarneri, BS, CCRP, Roger Pearse, MD PhD, Adriana C Rossi, MD MSc, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Adrienne A. Phillips, MD MPH, Jingmei Hsu, MD, Ljiljana V. Vasovic, MD, Yen-Michael S. Hsu, MD PhD, Koen van Besien, MD PhD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140811

Published: 2020

Journal Articles

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Cara A. Rosenbaum, MD, Danny Luan, BS, MPH, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Koen Van Besien, MD PhD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 2026.

https://doi.org/10.1182/blood-2019-127710

Published: 2019

Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD

Blood (2019) 134 (Supplement_1): 4579.

https://doi.org/10.1182/blood-2019-127723

Published: 2019

Journal Articles

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Blood (2019) 134 (Supplement_1): 5644.

https://doi.org/10.1182/blood-2019-130914

Published: 2019

Journal Articles

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

Jorge Monge, MD, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Jin Guo, MD, Jorge Contreras, MD, Kathleen Pogonowski, RN, Natalie Agudo, RN, Danielle Guarneri, BS, CCRP, Brielle Liotta, BS, Eloisi Caldas Lopes, PhD, Roger Pearse, MD PhD, Morton Coleman, MD, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2019) 134 (Supplement_1): 5563.

https://doi.org/10.1182/blood-2019-127697

Published: 2019

Journal Articles

A Phase II Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed By Autologous Stem Cell Transplant for Patients with Multiple Myeloma

Alexandra Gomez-Arteaga, MD, Tomer M Mark, MDMSc, Danielle Guarneri, Paul J Christos, Dr.P.H., M.S., Usama Gergis, MD, June Greenberg, RN, Jingmei Hsu, MD PhD, Sebastian A. Mayer, MD, Ruben Niesvizky, MD, Roger Pearse, MD PhD, Adrienne A. Phillips, MD MPH, Adriana C. Rossi, MDMSc, Morton Coleman, MD, Koen Van Besien, MD PhD, Tsiporah B. Shore, MD

Blood (2017) 130 (Supplement 1): 4546.

https://doi.org/10.1182/blood.V130.Suppl_1.4546.4546

Published: 2017

Journal Articles

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Benjamin Diamond, MD, David S Jayabalan, MSc, Roger Pearse, MD PhD, Art Perry, Karen Pekle, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2017) 130 (Supplement 1): 3102.

https://doi.org/10.1182/blood.V130.Suppl_1.3102.3102

Published: 2017

Journal Articles

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Adriana C Rossi, MD, Ekta Aneja, MBBS, Angelique Boyer, David Jayabalan, BSMS, MSc, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4754.

https://doi.org/10.1182/blood.V124.21.4754.4754

Published: 2014

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Abbe Schickner, BA, John N. Allan, MD, Adriana C Rossi, MD, Roger Pearse, MD PhD, Linda Tegnestam, RN, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pognowski, RN, David Jayabalan, BSMS, MSc, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4761.

https://doi.org/10.1182/blood.V124.21.4761.4761

Published: 2014

Journal Articles

Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50

Joanna Rhodes, MD, Koen van Besien, MD, Hongtao Liu, MDPhD, Usama Gergis, MD, Stephanie B. Tsai, MD MA, Sebastian Mayer, MD, Wendy Stock, MD, Richard A. Larson, MD, Tsiporah B. Shore, MD, Olatoyosi Odenike, MD, Roger Pearse, MD PhD, Lucy A Godley, MD PhD, Tomer M Mark, MD MSc, Justin Kline, MD, Michael R. Bishop, MD, Andrew S. Artz, MD MS

Blood (2014) 124 (21): 1235.

https://doi.org/10.1182/blood.V124.21.1235.1235

Published: 2014

Journal Articles

Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)

Ekta Aneja, MBBS, Adriana C Rossi, MD, Tomer M Mark, MD MSc, David Jayabalan, BSMS, MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Art Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 5778.

https://doi.org/10.1182/blood.V124.21.5778.5778

Published: 2014

Journal Articles

Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF

John N. Allan, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Adriana C Rossi, MD, Linda Tegnestam, RN, Duane C Hassane, PhD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 2452.

https://doi.org/10.1182/blood.V124.21.2452.2452

Published: 2014

Journal Articles

Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.

Blood (2009) 114 (22): 2868.

https://doi.org/10.1182/blood.V114.22.2868.2868

Published: 2009

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Tomer Mark, MD, Morton Coleman, MD, David S Jayabalan, BSMS, Roger Pearse, MD/PhD, Faiza Zafar, PA, Scott Ely, MD, MPH, Megan C. Manco, Mary Crann, RN, John P. Leonard, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2009) 114 (22): 1861.

https://doi.org/10.1182/blood.V114.22.1861.1861

Published: 2009

Journal Articles

Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma.

Jessica L. Stern, Brian Di Carlo, MD, Michael W. Schuster, MD, Tsiporah B. Shore, MD, John G. Harpel, MD,PhD, Roger Pearse, MD,PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 2953.

https://doi.org/10.1182/blood.V108.11.2953.2953

Published: 2006

Journal Articles

Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease.

Hearn J. Cho, MD, PhD, Scott Ely, MD, Wayne R. Austin, AB, Ruben Niesvizky, MD, Roger Pearse, MD, PhD, Morton Coleman, MD, Nina Bhardwaj, MD, PhD, Maurizio DiLiberto, PhD, Selina Chen-Kiang, PhD, Lloyd J. Old, MD, Achim A. Jungbluth, MD

Blood (2006) 108 (11): 3397.

https://doi.org/10.1182/blood.V108.11.3397.3397

Published: 2006

Journal Articles

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Brian A. Di Carlo, MD, Jessica L. Stern, Michael Schuster, MD, Tsiporah Shore, MD, John Harpel, MD, PhD, Roger Pearse, MD, PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, MA, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 3538.

https://doi.org/10.1182/blood.V108.11.3538.3538

Published: 2006

Journal Articles

Multimodular Analysis of Angiogenic Biomarkers in the Primary Treatment of Multiple Myeloma: Correlative Studies of the BiRD Trial.

David K. Jin, MD, PhD, Lauren M. Young, BS, Loic Vincent, PhD, Udi Gelbshtein, BS, Karen Pekle, BS, George Lam, BS, Koji Shido, BS, Hearn J. Cho, MD, PhD, Roger Pearse, MD, PhD, John P. Leonard, MD, Selina Chen-Kiang, PhD, Morton Coleman, MD, Shahin Rafii, MD, Ruben Niesvizky, MD

Blood (2005) 106 (11): 3483.

https://doi.org/10.1182/blood.V106.11.3483.3483

Published: 2005

Journal Articles

Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.

Zoe Goldberg*, MD, Scott Ely, MD, Selina Chen-Kiang, PhD, Martha Chesi, PhD, Peter L. Bergsagel, MD, Karen Pekle*, RN, Larry Lyons*, Udi Gelbshtein*, Roger Pearse, MD, PhD, John Harpel, MD, PhD, Hearn Cho, MD, PhD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2004) 104 (11): 1497.

https://doi.org/10.1182/blood.V104.11.1497.1497

Published: 2004

NARROW

Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution

A Phase II Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed By Autologous Stem Cell Transplant for Patients with Multiple Myeloma

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin ® ), Lenalidomide/(Revlimid ® ), Dexamethasone) for Newly-Diagnosed Multiple Myeloma

Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50

Effect of Autologous Transplantation on PFS2 in Myeloma Patients Receiving Front-Line Bird (clarithromycin, lenalidomide, dexamethasone)

Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF

Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma.

Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease.

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Multimodular Analysis of Angiogenic Biomarkers in the Primary Treatment of Multiple Myeloma: Correlative Studies of the BiRD Trial.

Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only